Home › Juvenile Arthritis › Ohio › Cleveland
Juvenile Arthritis clinical trials in Cleveland, OH
3 studies for Juvenile Arthritis are looking for participants at sites in and around Cleveland (within about 30 miles). Open a study to see who can join and how to contact the study team.
Recruiting for a study here? Feature it at the top of this page — $99 for 30 days →
Study to Evaluate the Pharmacokinetics (PK), Safety and Tolerability up to 6 Years of Intravenous (i.v.) Secukinumab in Pediatric Participants With Juvenile Psoriatic Arthritis (JPsA).
RecruitingPhase 1
- Univ Hosp Cleveland Medical Center, Cleveland
Observational Study of Pediatric Rheumatic Diseases: The CARRA Registry
RecruitingObservational study
- Metrohealth Medical Center, Cleveland
- Cleveland Clinic Foundation, Cleveland
A Study to Assess Adverse Events, Change in Disease Activity, and How the Drug Moves Through the Body in Children With Juvenile Psoriatic Arthritis (jPsA) Receiving Subcutaneously Injected Risankizumab or Adalimumab
RecruitingPhase 3
- MetroHealth Medical Center /ID# 262377, Cleveland
- Cleveland Clinic - Cleveland /ID# 276655, Cleveland
About Juvenile Arthritis
Juvenile arthritis or JA, causes joint swelling, pain, stiffness and loss of motion in children. Learn diagnosis and tests for JA.
More about Juvenile Arthritis on MedlinePlus
Juvenile Arthritis trials in other cities
- Cincinnati, OH6 studies
- Washington, DC6 studies
- Portland, OR5 studies
- Pittsburgh, PA4 studies
- New York City, NY4 studies
- Salt Lake City, UT4 studies
- Gainesville, FL3 studies
- Indianapolis, IN3 studies
Other studies in Cleveland
- Non-Small Cell Lung Cancer48 studies
- Cancer (all types)36 studies
- Breast Cancer33 studies
- Heart Failure31 studies
- Metastatic Cancer30 studies
- Prostate Cancer30 studies
- Ovarian Cancer29 studies
- Lung Cancer26 studies
- Colorectal Cancer25 studies
- Acute Myeloid Leukemia20 studies
- Head and Neck Squamous Cell Carcinoma20 studies
- Cardiovascular Disease20 studies
From ClinicalTrials.gov, data retrieved Nov 15, 2026. Each study sets its own eligibility; the study team decides who can join.